Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and PolyPid (NASDAQ:PYPD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.
Risk and Volatility
Vivos Therapeutics has a beta of 6.1, suggesting that its stock price is 510% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.
Insider and Institutional Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -127.70% | -2,325.64% | -98.12% |
| PolyPid | N/A | -241.96% | -126.91% |
Earnings and Valuation
This table compares Vivos Therapeutics and PolyPid”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.69 | -$21.17 million | ($2.14) | -0.40 |
| PolyPid | N/A | N/A | -$34.17 million | ($1.91) | -2.36 |
Vivos Therapeutics has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Vivos Therapeutics and PolyPid, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| PolyPid | 1 | 0 | 5 | 0 | 2.67 |
Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 223.89%. PolyPid has a consensus target price of $12.25, indicating a potential upside of 172.22%. Given Vivos Therapeutics’ higher possible upside, research analysts plainly believe Vivos Therapeutics is more favorable than PolyPid.
Summary
PolyPid beats Vivos Therapeutics on 7 of the 13 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
